NightHawk Biosciences Inc (NHWK)

[RNsidersbuying]

...Specifically, our latest pre-clinical studies demonstrated immunogenicity proof-of-concept, validating that the selected vaccine antigen may be appropriate for human testing. Preclinical testing demonstrated expansion of antibody-supporting CD4+, and virus killing CD8+ T-cells in the lungs of the animals, a major site for COVID-19 infection. We believe this platform may play an important role as a standalone vaccine or in combination with other antibody-generating vaccines to provide broad cellular T-cell and humoral protection against COVID-19, particularly for elderly patients and those with underlying health conditions who have an increased risk of complications and death from COVID-19."

https://www.heatbio.com/news-media/news-releases/detail/668/heat-biologics-provides-second-quarter-2020-business-update

I would've guessed they were closer than "may be appropriate"? Will we get a fill of that 1.50 hitch in the chart...possibly also that second hitch at 1.00?

https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=htbx&insttype=&freq=1&show=&time=4